Immunic Inc Chief Medical Officer Discusses Promising Treatments for IBD on World IBD Day
Immunic Inc Chief Medical Officer Discusses Promising Treatments for IBD on World IBD Day
Key Takeaways (TLDR)
Immunic Inc. is exploring new therapies for IBD, including a drug that strengthens the bowel barrier, giving them an advantage in the IBD treatment market.
IBD is characterized by an immune response triggered by the interaction between gut bacteria and the immune system, leading to bowel wall damage and ulcerations. Current management includes immunosuppressive drugs.
The new therapies being explored by Immunic Inc. have the potential to make the world a better place by providing treatments for IBD that do not suppress the immune system, thus improving the quality of life for those affected.
The recent phase two trial with Vidofludimus calcium (IMU-838) in ulcerative colitis showed promising results in maintaining remission, marking a significant breakthrough in IBD treatment.
Why it Matters
Inflammatory Bowel Disease affects a significant portion of the population and can have a major impact on daily life. The discussion of promising treatments, including new drugs that do not suppress the immune system, provides hope for improved management and potential remission for IBD patients. This news highlights the ongoing efforts of Immunic Inc. to develop innovative therapies for IBD, offering potential solutions for those affected by the condition.
Summary
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses Inflammatory Bowel Disease (IBD) with Proactive's Stephen Gunnion to mark World IBD Day on May 19. Muehler explained that IBD encompasses Crohn's disease and ulcerative colitis, characterised by an immune response triggered by the interaction between gut bacteria and the immune system, leading to bowel wall damage and ulcerations. This condition affects 1-2% of the population, presenting significant social challenges due to symptoms like diarrhoea and abdominal pain, which can limit social and professional activities. Currently, IBD is managed with immunosuppressive drugs, which, while effective, increase susceptibility to infections and other autoimmune diseases and often show immunosuppression. Dr Muehler highlighted the need for treatments that do not suppress the immune system. Immunic Inc. has been exploring new therapies, including a drug that strengthens the bowel barrier. A recent phase two trial with Vidofludimus calcium (IMU-838) in ulcerative colitis showed promising results in maintaining remission. This drug, primarily tested in multiple sclerosis, is part of a class not previously tested in large IBD trials. Another promising drug, IMU-856, aims to regenerate the bowel barrier, preventing harmful interactions between gut bacteria and the immune system without immunosuppression. This drug has shown positive results in animal experiments as well as in healthy volunteers and celiac disease trials. Immunic currently evaluates potential testing of IMU-856 in IBD.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Immunic Inc Chief Medical Officer Discusses Promising Treatments for IBD on World IBD Day.